array:19 [
  "pii" => "X0211699500025690"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2000-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2000;20 Supl 1:35"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 2656
    "formatos" => array:3 [
      "EPUB" => 164
      "HTML" => 2139
      "PDF" => 353
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699500025682"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:36"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3777
      "formatos" => array:3 [
        "EPUB" => 170
        "HTML" => 3220
        "PDF" => 387
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "«ASPECTOS ACTUALES DEL CONTROL DE LA PRESIÓN ARTERIAL» Epidemiología de la hipertensión arterial y situación actual del control de presión en España"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "36"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "A. COCA"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "A. COCA"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025682?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025682/v0_201502091333/es/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699500025705"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:34"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2398
      "formatos" => array:3 [
        "EPUB" => 158
        "HTML" => 1949
        "PDF" => 291
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Riesgo cardiovascular en diabetes y nefropatía"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "34"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "R. ROMERO"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "R. ROMERO"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025705?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025705/v0_201502091333/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Alpha-blockers in the Treatment of Hypertension"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "35"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "M. KAPLAN"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "M. KAPLAN"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XX. Suplemento 1. 2000 Alpha-blockers in the Treatment of Hypertension M. Kaplan University of Texas Southwestern. Medical Center at Dallas. Selective alpha1-blockers act as vasodilators, both on arteries and veins. The specificity for alpha-adrenoreceptors induces relaxation of vascular smooth muscle with little reflex stimulation of cardiac output because catecholamine release is modulated via nonblocked alpha-receptors. As a result, peripheral resistance falls during rest and during various cardiovascular stresses, while cardiac output remains unchanged or slightly increased and cardiovascular reflex-control mechanisms are well maintained. These favorable haemodynamic effects have been demonstrated during exercise, when they particularly contrast with the effects of beta-adrenergic receptor blockers, which are often poorly tolerated by athletes. The various selective alpha1-blockers differ from each other according to their pharmacokinetic and pharmacodynamic properties. These properties have been examined for prazosin, the first and for over 10 years the only member of this class available&#59; terazosin, introduced in 1987, and doxazosin, which became available in 1991. Terazosin and doxazosin are less lipid soluble and have half or less of the affinity for alpha1-receptors than does prazosin. For these and other reasons, they induce a less rapid and less profound initial fall in blood pressure, particularly after standing, than does prazosin. These may translate into differences in the propensity for first-dose and subsequent hypotensive symptoms and certainly provides for a longer duration of action for the second-generation alpha1-blockers. More recently, a controlled-release doxazosin gastrointestinal therapeutic system (GITS) have been developed. This GITS system in an osmotic pump that slowly releases the active drug so that peak levels are achieved 10 to 12 hours after oral intake. The plasma drug concentration declines more gradually for the doxazosin GITS formulation than the stan- dard doxazosin tablet, providing high blood levels even at the end of 24 hours. These long-acting alpha-blockers have been found to lower both systolic and diastolic blood pressure by approximately 10 mm Hg in multiple groups of patients with mild-to-moderate hypertension. In a multicentre trial, doxazosin was equally effective in patients over the age of 65 years and in younger patients, as well as in both black and nonblack patients. In double-blind randomized parallel group comparisons made between the newly marketed doxazosin GITS formulation and the standard doxazosin tablets, doxazosin GITS was well tolerated and fewer patients on the GITS formulation discontinued therapy because of side effects and syncope was not seen with the GITS preparation. Unfortunately, alpha-blockers have not been included in the multiple randomized placebo-controlled trials performed over the past 30 years that have proved the ability of antihypertensive therapy to reduce cardiovascular morbidity and mortality. The situation is in process of changing. In particular, the massive Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), which will be completed in 2003, is comparing the ability of a calcium channel blocker (amlodipine), an ACE inhibitor (lisinopril) and an alpha-blocker (doxazosin) with a diuretic to reduce cardiovascular mortality and morbidity in almost 45,000 high-risk hypertensives. In the meantime, alpha-blockers are widely recommended for the initial choice of therapy in hypertensives with one or more comorbid conditions, including dyslipidaemia, diabetes and prostatism. BIBLIOGRAFÍA 1. Kaplan NM: Chapter 7: Treatment of hypertension: Drug Therapy in Clinical Hypertension 7th ed. Williams and Wilkins, 1998. 2. Os I and Stokke HP: Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. J Cardiovascular Pharmacology 33: 791-797, 1999. Correspondence: Norman M., Kaplan M. D. University of Texas Southwestern Medical Center at Dallas 5323 Harry Hines Blvd. Dallas, TX 75235-8899 35 "
    "pdfFichero" => "P7-E170-S140-A1885.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025690/v0_201502091333/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000020000000S1/v0_201502091333/X0211699500025690/v0_201502091333/en/P7-E170-S140-A1885.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025690?idApp=UINPBA000064"
]
Compartir
Información de la revista

Estadísticas

Siga este enlace para acceder al texto completo del artículo

Alpha-blockers in the Treatment of Hypertension
M. KAPLAN
Leído
9177
Veces
se ha leído el artículo
2419
Total PDF
6758
Total HTML
Compartir estadísticas
 array:19 [
  "pii" => "X0211699500025690"
  "issn" => "02116995"
  "estado" => "S300"
  "fechaPublicacion" => "2000-02-01"
  "documento" => "article"
  "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
  "subdocumento" => "fla"
  "cita" => "Nefrologia. 2000;20 Supl 1:35"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:2 [
    "total" => 2656
    "formatos" => array:3 [
      "EPUB" => 164
      "HTML" => 2139
      "PDF" => 353
    ]
  ]
  "itemSiguiente" => array:15 [
    "pii" => "X0211699500025682"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:36"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 3777
      "formatos" => array:3 [
        "EPUB" => 170
        "HTML" => 3220
        "PDF" => 387
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "«ASPECTOS ACTUALES DEL CONTROL DE LA PRESIÓN ARTERIAL» Epidemiología de la hipertensión arterial y situación actual del control de presión en España"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "36"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "A. COCA"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "A. COCA"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025682?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025682/v0_201502091333/es/main.assets"
  ]
  "itemAnterior" => array:15 [
    "pii" => "X0211699500025705"
    "issn" => "02116995"
    "estado" => "S300"
    "fechaPublicacion" => "2000-02-01"
    "documento" => "article"
    "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/"
    "subdocumento" => "fla"
    "cita" => "Nefrologia. 2000;20 Supl 1:34"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:2 [
      "total" => 2398
      "formatos" => array:3 [
        "EPUB" => 158
        "HTML" => 1949
        "PDF" => 291
      ]
    ]
    "es" => array:8 [
      "idiomaDefecto" => true
      "titulo" => "Riesgo cardiovascular en diabetes y nefropatía"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:1 [
          "paginaInicial" => "34"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "R. ROMERO"
          "autores" => array:1 [
            0 => array:1 [
              "nombre" => "R. ROMERO"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025705?idApp=UINPBA000064"
    "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025705/v0_201502091333/es/main.assets"
  ]
  "en" => array:8 [
    "idiomaDefecto" => true
    "titulo" => "Alpha-blockers in the Treatment of Hypertension"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:1 [
        "paginaInicial" => "35"
      ]
    ]
    "autores" => array:1 [
      0 => array:2 [
        "autoresLista" => "M. KAPLAN"
        "autores" => array:1 [
          0 => array:1 [
            "nombre" => "M. KAPLAN"
          ]
        ]
      ]
    ]
    "textoCompleto" => "NEFROLOGÍA. Vol. XX. Suplemento 1. 2000 Alpha-blockers in the Treatment of Hypertension M. Kaplan University of Texas Southwestern. Medical Center at Dallas. Selective alpha1-blockers act as vasodilators, both on arteries and veins. The specificity for alpha-adrenoreceptors induces relaxation of vascular smooth muscle with little reflex stimulation of cardiac output because catecholamine release is modulated via nonblocked alpha-receptors. As a result, peripheral resistance falls during rest and during various cardiovascular stresses, while cardiac output remains unchanged or slightly increased and cardiovascular reflex-control mechanisms are well maintained. These favorable haemodynamic effects have been demonstrated during exercise, when they particularly contrast with the effects of beta-adrenergic receptor blockers, which are often poorly tolerated by athletes. The various selective alpha1-blockers differ from each other according to their pharmacokinetic and pharmacodynamic properties. These properties have been examined for prazosin, the first and for over 10 years the only member of this class available&#59; terazosin, introduced in 1987, and doxazosin, which became available in 1991. Terazosin and doxazosin are less lipid soluble and have half or less of the affinity for alpha1-receptors than does prazosin. For these and other reasons, they induce a less rapid and less profound initial fall in blood pressure, particularly after standing, than does prazosin. These may translate into differences in the propensity for first-dose and subsequent hypotensive symptoms and certainly provides for a longer duration of action for the second-generation alpha1-blockers. More recently, a controlled-release doxazosin gastrointestinal therapeutic system (GITS) have been developed. This GITS system in an osmotic pump that slowly releases the active drug so that peak levels are achieved 10 to 12 hours after oral intake. The plasma drug concentration declines more gradually for the doxazosin GITS formulation than the stan- dard doxazosin tablet, providing high blood levels even at the end of 24 hours. These long-acting alpha-blockers have been found to lower both systolic and diastolic blood pressure by approximately 10 mm Hg in multiple groups of patients with mild-to-moderate hypertension. In a multicentre trial, doxazosin was equally effective in patients over the age of 65 years and in younger patients, as well as in both black and nonblack patients. In double-blind randomized parallel group comparisons made between the newly marketed doxazosin GITS formulation and the standard doxazosin tablets, doxazosin GITS was well tolerated and fewer patients on the GITS formulation discontinued therapy because of side effects and syncope was not seen with the GITS preparation. Unfortunately, alpha-blockers have not been included in the multiple randomized placebo-controlled trials performed over the past 30 years that have proved the ability of antihypertensive therapy to reduce cardiovascular morbidity and mortality. The situation is in process of changing. In particular, the massive Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), which will be completed in 2003, is comparing the ability of a calcium channel blocker (amlodipine), an ACE inhibitor (lisinopril) and an alpha-blocker (doxazosin) with a diuretic to reduce cardiovascular mortality and morbidity in almost 45,000 high-risk hypertensives. In the meantime, alpha-blockers are widely recommended for the initial choice of therapy in hypertensives with one or more comorbid conditions, including dyslipidaemia, diabetes and prostatism. BIBLIOGRAFÍA 1. Kaplan NM: Chapter 7: Treatment of hypertension: Drug Therapy in Clinical Hypertension 7th ed. Williams and Wilkins, 1998. 2. Os I and Stokke HP: Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. J Cardiovascular Pharmacology 33: 791-797, 1999. Correspondence: Norman M., Kaplan M. D. University of Texas Southwestern Medical Center at Dallas 5323 Harry Hines Blvd. Dallas, TX 75235-8899 35 "
    "pdfFichero" => "P7-E170-S140-A1885.pdf"
    "tienePdf" => true
  ]
  "idiomaDefecto" => "en"
  "url" => "/02116995/00000020000000S1/v0_201502091333/X0211699500025690/v0_201502091333/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "35407"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Suplementos"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/02116995/00000020000000S1/v0_201502091333/X0211699500025690/v0_201502091333/en/P7-E170-S140-A1885.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699500025690?idApp=UINPBA000064"
]
Información del artículo
ISSN: 02116995
Idioma original: Inglés
Datos actualizados diariamente
año/Mes Html Pdf Total
2024 Noviembre 10 12 22
2024 Octubre 57 71 128
2024 Septiembre 71 42 113
2024 Agosto 96 67 163
2024 Julio 76 80 156
2024 Junio 70 69 139
2024 Mayo 115 96 211
2024 Abril 78 37 115
2024 Marzo 69 44 113
2024 Febrero 71 53 124
2024 Enero 57 35 92
2023 Diciembre 65 38 103
2023 Noviembre 85 57 142
2023 Octubre 83 38 121
2023 Septiembre 60 24 84
2023 Agosto 82 31 113
2023 Julio 85 46 131
2023 Junio 97 32 129
2023 Mayo 83 30 113
2023 Abril 43 23 66
2023 Marzo 71 30 101
2023 Febrero 59 29 88
2023 Enero 67 33 100
2022 Diciembre 48 26 74
2022 Noviembre 68 42 110
2022 Octubre 56 42 98
2022 Septiembre 35 28 63
2022 Agosto 45 36 81
2022 Julio 44 35 79
2022 Junio 75 40 115
2022 Mayo 53 29 82
2022 Abril 50 43 93
2022 Marzo 36 41 77
2022 Febrero 100 42 142
2022 Enero 123 30 153
2021 Diciembre 143 47 190
2021 Noviembre 95 39 134
2021 Octubre 72 41 113
2021 Septiembre 75 44 119
2021 Agosto 75 38 113
2021 Julio 65 50 115
2021 Junio 82 19 101
2021 Mayo 117 38 155
2021 Abril 206 59 265
2021 Marzo 161 14 175
2021 Febrero 165 21 186
2021 Enero 90 21 111
2020 Diciembre 93 29 122
2020 Noviembre 86 10 96
2020 Octubre 73 7 80
2020 Septiembre 49 8 57
2020 Agosto 64 16 80
2020 Julio 88 21 109
2020 Junio 100 27 127
2020 Mayo 84 20 104
2020 Abril 84 16 100
2020 Marzo 112 18 130
2020 Febrero 114 19 133
2020 Enero 127 23 150
2019 Diciembre 78 18 96
2019 Noviembre 70 13 83
2019 Octubre 78 14 92
2019 Septiembre 109 21 130
2019 Agosto 54 12 66
2019 Julio 46 13 59
2019 Junio 38 15 53
2019 Mayo 54 7 61
2019 Abril 115 24 139
2019 Marzo 47 10 57
2019 Febrero 27 16 43
2019 Enero 21 16 37
2018 Diciembre 38 18 56
2018 Noviembre 32 8 40
2018 Octubre 40 12 52
2018 Septiembre 37 8 45
2018 Agosto 21 7 28
2018 Julio 24 8 32
2018 Junio 13 5 18
2018 Mayo 14 7 21
2018 Abril 22 3 25
2018 Marzo 10 4 14
2018 Febrero 14 6 20
2018 Enero 8 2 10
2017 Diciembre 22 4 26
2017 Noviembre 9 5 14
2017 Octubre 13 3 16
2017 Septiembre 5 4 9
2017 Agosto 23 9 32
2017 Julio 16 4 20
2017 Junio 22 6 28
2017 Mayo 14 2 16
2017 Abril 10 1 11
2017 Marzo 17 1 18
2017 Febrero 11 1 12
2017 Enero 6 1 7
2016 Diciembre 9 2 11
2016 Noviembre 29 1 30
2016 Octubre 47 4 51
2016 Septiembre 41 2 43
2016 Agosto 69 0 69
2016 Julio 104 6 110
2016 Junio 90 0 90
2016 Mayo 78 0 78
2016 Abril 30 0 30
2016 Marzo 27 0 27
2016 Febrero 33 0 33
2016 Enero 31 0 31
2015 Diciembre 34 0 34
2015 Noviembre 23 0 23
2015 Octubre 26 0 26
2015 Septiembre 32 0 32
2015 Agosto 29 0 29
2015 Julio 23 0 23
2015 Junio 8 0 8
2015 Mayo 14 0 14
Mostrar todo

Siga este enlace para acceder al texto completo del artículo

Idiomas
Nefrología
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?